Hoehn Thomas
Neonatology and Pediatric Intensive Care Medicine, Department of General Pediatrics, Heinrich-Heine-University, Moorenstr. 5 D-40225 Duesseldorf, Germany.
Pharmacol Ther. 2007 Jun;114(3):318-26. doi: 10.1016/j.pharmthera.2007.03.006. Epub 2007 Apr 20.
Pulmonary hypertension (PH) in newborns and infants can present in its idiopathic form or complicate a long list of other diseases. Most of these conditions are either pulmonary or cardiovascular in origin. In the present review our current knowledge regarding pathophysiology, structural changes, diagnosis, and available treatment options for PH in the age group below 1 year of age is summarized. New treatment options available in adults including endothelin receptor antagonists (ETRA) and phosphodiesterase (PDE) inhibitors are presented and the need for randomized controlled trials in newborns and infants is emphasized. Future candidates for pharmacotherapy of PH in infants include among others vasoactive intestinal polypeptide (VIP), PDE-3 and PDE-4 inhibitors, hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and adrenomedullin (ADM).
新生儿和婴儿的肺动脉高压（PH）可表现为特发性形式，或使一系列其他疾病复杂化。这些疾病大多起源于肺部或心血管系统。在本综述中，总结了我们目前关于1岁以下年龄组PH的病理生理学、结构变化、诊断和可用治疗方案的知识。介绍了成人可用的新治疗方案，包括内皮素受体拮抗剂（ETRA）和磷酸二酯酶（PDE）抑制剂，并强调了在新生儿和婴儿中进行随机对照试验的必要性。婴儿PH药物治疗的未来候选药物包括血管活性肠肽（VIP）、PDE-3和PDE-4抑制剂、羟甲基戊二酰辅酶A（HMG-CoA）还原酶抑制剂和肾上腺髓质素（ADM）等。
